Skip to main content

Table 2 Early virologic (EVR) and sustained virologic response (SRV) according to the genotype and population characteristics.

From: Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

Characteristics

EVR Genotype 1

EVR Genotype 3

P value

SVR Genotype 1

SVR Genotype 3

P value

Sex

      

Men

23% (13/5)

65% (13/20)

0.9917

27% (17/62)

32% (10/3)

0.7612

Women

30% (7/23)

83% (5/6)

 

22% (6/27)

33% (3/9)

 

Race Caucasian

28% (19/70)

60% (14/23)

0.7502

29% (14/47)

31% (12/38)

0.3662

Age

      

< 40 years

33% (3/9)

100% (4/4)

0.4856

40% (4/10)

50% (3/6)

0.2694

> 40 years

28% (19/67)

59% (13/22)

 

24% (18/75)

29% (10/34)

 

Alcohol abuse

      

Yes

22% (5/22)

20% (1/5)

0.1798

29% (8/27)

12% (1/8)

1.1

No

27% (15/55)

755 (15/20)

 

36% (15/41)

36% (12/33)

 

Exposure n (%)

      

IVDU

37% (6/16)

55% (5/9)

 

25% (4/16)

30% (4/13)

 

Parenteral

29% (8/27)

50% (3/6)

0.7038

25% (8/32)

36% (4/11)

1.073

Parenteral/IVDU

0% (0/3)

0% (0/1)

0.6794

0% (0/3)

25% (1/4)

1.053

Unknown

18% (6/32)

88% (8/9)

 

25% (4/16)

38% (5/13)

 
  1. p value < 0.005 = significant